Advicenne SA AI Stock Analysis
Want to see FR:ALDVI full AI Analyst Report?
Advicenne SA (ALDVI) AI Stock Analysis
Advicenne SA
(Paris:ALDVI)
The overall score is driven primarily by very weak financial strength, including deepening losses, negative equity, and shrinking assets, combined with a bearish technical picture and stretched valuation with a very high P/E and no dividend; oversold momentum readings and improving cash burn offer only limited offset to these significant risks.
Advicenne SA (ALDVI) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 9.52M
- Dividend Yield
- ―
- Average Volume (3M)
- 76.52K
- Price to Earnings (P/E)
- 218.5
- Beta (1Y)
- 0.64
- Revenue Growth
- 0.10%
- EPS Growth
- 99.69%
- Country
- France
- Employees
- 11
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Advicenne SA Business Overview & Revenue Model
Company Description
Advicenne S.A. operates as a specialized pharmaceutical firm, focusing on the innovation and commercialization of therapeutic solutions for various kidney-related disorders. The company's primary offering, Sibnayal, targets both distal renal tubular...
Advicenne SA Financial Statement Overview
Summary
Revenue is growing and gross margins have turned positive, but net losses are large and widening, equity is deeply negative, and assets have eroded, indicating high solvency risk and weak overall financial health.
Income Statement
25NegativeBalance Sheet
15Very NegativeCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.62M | 6.01M | 4.97M | 4.46M | 2.40M | 2.69M |
| Gross Profit | -4.75M | -922.00K | -1.18M | -6.31M | 1.28M | 1.72M |
| EBITDA | 2.45M | -7.81M | 1.35M | -6.23M | -9.70M | -12.02M |
| Net Income | 43.00K | -9.53M | -6.46M | -7.03M | -11.47M | -12.43M |
Balance Sheet | ||||||
| Total Assets | 7.54M | 7.14M | 9.51M | 12.41M | 14.26M | 18.88M |
| Cash, Cash Equivalents and Short-Term Investments | 1.55M | 1.34M | 3.25M | 5.25M | 8.32M | 12.69M |
| Total Debt | 21.18M | 19.00M | 18.19M | 18.32M | 18.75M | 12.54M |
| Total Liabilities | 29.16M | 33.51M | 28.58M | 24.38M | 24.88M | 18.57M |
| Stockholders Equity | -21.62M | -26.37M | -19.07M | -11.97M | -10.50M | 309.00K |
Cash Flow | ||||||
| Free Cash Flow | -4.11M | -4.11M | -853.00K | -7.27M | -9.26M | -12.82M |
| Operating Cash Flow | -3.73M | -3.73M | -762.00K | -5.99M | -9.15M | -12.53M |
| Investing Cash Flow | -403.00K | -403.00K | -108.00K | -1.32M | -2,000 | -395.00K |
| Financing Cash Flow | 2.23M | 2.23M | -1.13M | 4.23M | 4.78M | 8.85M |
Advicenne SA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALDVI, the sentiment is Neutral. The current price of 0.65 is above the 20-day moving average (MA) of 0.65, below the 50-day MA of 0.71, and below the 200-day MA of 1.31, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 43.30 is Neutral, neither overbought nor oversold. The STOCH value of 27.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:ALDVI.
Advicenne SA Peers Comparison
Overall Rating
FR:SIGHT46Neutral
FR:ABNX42Neutral
FR:ALSEN41Neutral- FR:ALDVI38Underperform
FR:ALNEV37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| FR:SIGHT | 46Neutral | EUR 18.44M | -1.02 | 52.39% | ― | -610.31% | 43.88% |
| FR:ABNX | 42Neutral | EUR 71.98M | -7.71 | -80.82% | ― | -10.38% | -72.05% |
| FR:ALSEN | 41Neutral | EUR 81.46M | -1.95 | -54.15% | ― | ― | 6.26% |
| FR:ALDVI | 38Underperform | EUR 9.52M | 218.48 | -0.18% | ― | 0.10% | 99.69% |
| FR:ALNEV | 37Underperform | EUR 132.98K | 0.00 | -26.52% | ― | -44.46% | 100.00% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:ALDVI | Advicenne SA | 0.65 | -0.99 | -60.26% | |
| FR:SIGHT | GenSight Biologics | 0.07 | -0.04 | -35.09% | |
| FR:ABNX | ABIONYX Pharma SA | 1.70 | -2.26 | -57.06% | |
| FR:ALSEN | Sensorion SAS | 8.28 | -9.02 | -52.14% | |
| FR:ALNEV | Neovacs SA | 0.08 | -269.92 | -99.97% |
Advicenne SA Corporate Events
Advicenne Sets November 9 Hearing in Safeguard Proceedings
Advicenne is a pharmaceutical company developing and commercializing treatments for rare kidney and neurological diseases, particularly nephrology products. Its lead drug, Sibnayal, is approved in several markets for distal renal tubular acidosis and...
Advicenne Extends Financial Runway to 2028 with New Bond Tranche
Advicenne has received the remaining €1 million tranche of a bond financing agreement with a fund managed by L1 Capital, lifting its cash position and extending its financial runway from mid-2027 to 2028. The improved visibility is underpinned by str...
Advicenne swings to profit as Sibnayal growth and French pricing deals cut debt
Advicenne reported a sharp improvement in its first-half 2026 performance, turning a €4.62 million net profit versus a loss a year earlier, driven by price agreements for Sibnayal and Likozam in France and strong growth in Sibnayal sales across Europ...
Advicenne Pulls U.S. Application for Rare Kidney Drug ADV7103 After FDA Feedback
Advicenne has voluntarily withdrawn its New Drug Application to the U.S. Food and Drug Administration for ADV7103 in primary distal renal tubular acidosis, after regulators indicated that additional Chemistry, Manufacturing and Controls work is requi...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 19, 2026